Evidence map›Paper›PMID 34112172›Full record

ArticleBMC complementary medicine and therapies2021

Polysaccharides from Ganoderma Sinense - rice bran fermentation products and their anti-tumor activities on non-small-cell lung cancer.

Wei Han, Hongjuan Chen, Lin Zhou, Haijie Zou, Xiaohong Luo, Bo Sun, Xuhui Zhuang

Open access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. A Review ofFoods (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wei HanAcademy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China.
Hongjuan ChenAcademy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China.
Lin ZhouChina National Tranditional Chinese Medicine Co., Ltd, Beijing, 100077, P. R. China.
Haijie ZouAcademy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China.
Xiaohong LuoAcademy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China.
Bo SunAcademy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China.
Xuhui ZhuangAcademy of National Food and Strategic Reserves Administration, Beijing, 100037, P. R. China. zxh@ags.ac.cn.ORCID http://orcid.org/0000-0003-1800-8046
Academy of State Administration of Grain · CN

Funding

Grant Fund for Basic Science, Research of Central Nonprofit Academe ZX 1939Grant Fund for Basic Science, Research of Central Nonprofit Academe ZX 1940Grant Fund for Basic Science, Research of Central Nonprofit Academe ZX 1941National Key Research and Development Program of China (CN) 2016YFD0400804
6 · The paper itself

Abstract

backgroundNon-small-cell lung cancer (NSCLC) accounts more than 80% of the lung cancer cases. Polysaccharides in rice bran and its fermentation products have been proven to suppress many cancers. However, the report on inhibiting NSCLC is few. In this paper, the polysaccharides with suppression activity to H1299 NSCLC in the fermentation products of full-fat rice bran and defatted rice bran were studied in vitro and in vivo.

methodPolysaccharides (GSRBPs) were extracted from Ganoderma sinense - full-fat rice bran (GS-FRB) and Ganoderma sinense - defatted rice bran (GS-DRB) fermentation products. The structure information of the GSRBPs was studied using HPLC analysis. The anti-tumor activities on H1299 NSCLC of GSRBPs in vitro study was performed using MTT method. The in vivo studies use BALB/c-nu nude mice as H1299 NSCLC bearing mice.

resultAll the polysaccharides contained two fractions, GSFPS-1 and GSFPS-2. The molecular weight and the ratio of GSFPS-1 and GSFPS-2 were different in GS-FRB and GS-DRB. At the earlier state of fermentation, all polysaccharides were composed of D-glu, D-man, D-xyl and L-ara with certain molar ratios. But at the latter stage, polysaccharides in GS-FRB were composed of D-glu, D-man, D-xyl, L-ara and D-fru, while these in GS-DRB only composed of D-glu and D-man. In the in vitro study, the IC50 of RBS and GSRBPs was as GS-DRB-11 (40.62 μg/mL), GS-FRB-9 (43.82 μg/mL), GS-DRB-7 (48.08 μg/mL), RBS (49.56 μg/mL), GS-DRB-9 (49.91 μg/mL), GS-DRB-13 (51.89 μg/mL), GS-FRB-11 (53.75 μg/mL), GS-FRB-7 (56.84 μg/mL), GS-DRB-13 (60.63 μg/mL) from small to large. In the in vivo study, the H1299 NSCLC inhibition rate (InRa) of RBS and GSRBPs were GS-DRB-11 (86.81%) > GS-DRB-9 (86.01%) > GS-FRB-9 (84.88%) > GS-DRB-7 (82.21%) > GS-DRB-13 (78.04%) > RBS (76.06%) > GS-FRB-13 (65.44%) > GS-FRB-11 (64.70%) > GS-FRB-7 (27.87%). The GSFPS-2 area percent was negatively correlated to the IC50 and was positively correlated to the InRa. This means the GSFPS-2 had much higher anti-tumor activity than GSFPS-1.

conclusionGSFPS-2 had higher anti-tumor activities, and the lipid in the rice bran has a decisive effect on the structures of polysaccharides produced by fermentation. Therefore, GSRBPs could be considered as potential novel agents to suppress H1299 non-small-cell lung cancer.

Indexed as

AnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorFermentationGanodermaLung NeoplasmsMiceMice, Inbred BALB CMice, NudeOryzaPolysaccharidesPolysaccharidesAnti-tumor activityGanoderma sinense fermentationH1299 non-small-cell lung cancerIn vivo and in vitroRice bran polysaccharides

Identifiers

PMID34112172
PMCPMC8194173
OpenAlexW3171296445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.